An interventional study of DIGIPARK MONITOR in Parkinson Disease, sponsored by DIAMPARK. Not yet recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-09.
Sponsored by DIAMPARK · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.
Among the 428 studies in Parkinson Disease with a site in France, this one is the 49th largest by planned enrollment of the 328 interventional ones that give a count, is one of 15 that started in 2024, is one of 179 with no phase, reaches primary completion later than 34 of the 75 other live ones, and was the 388th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital Tuebingen · Sites in France, Germany, Italy and 4 more countries
Ages 35–80
Hospices Civils de Lyon · Sites in France
Ages 20–80 · Healthy volunteers
University Hospital, Grenoble · Sites in France
Ages 18–85 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
428 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 67 · Phase 3 52 · Phase 4 17
First in 1990; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 64 across the 328 interventional studies, 90 across the 98 observational. Of the 318 that completed or were terminated, 60 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 428 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with DIAMPARK as lead sponsor.
DIAMPARK has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Parkinson Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT04179695University Hospital, LilleEvaluation of a New Communication Aid Tool to Favor Global Patient Centered Care | 2026-12 |
| NCT07083089Cilcare SASEarly Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) | 2026-12 |
| NCT06401395DIAMPARKClinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING) | 2027-01-01 |
| NCT06576713University Hospital, Strasbourg, FranceCombined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism | 2027-01-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 428 studies in Parkinson Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) ranks second among neurodegenerative diseases and is a major cause of neurological motor disability. The number of PD cases doubled between 1990 and 2016. The consequences of PD, including an increased risk of falls, loss of autonomy and reduced quality of life, contribute to increased morbidity and mortality. The costs associated with falls in the elderly (a fortiori those with PD) and their consequences represent between 0.85% and 1.5% of total healthcare expenditure.
There is currently no cure for PD. Treatment is symptomatic and depends on the degree of functional impairment and the age of onset. After a period of stabilization (state phase) of varying length, the clinical situation worsens because of treatment-related motor complications (motor fluctuations, on/off phenomena, dyskinesias, under/overdosing) and the appearance or worsening of disease-specific signs linked to the pathogenic process. Treatment of motor complications involves constantly adjusting doses and dosing schedules to suit each individual case, and to take account of variations in the patient's motor status over the months. These adjustments must also take into account the non-motor signs of the disease, notably thymic fluctuations, treatment-related behavioral disorders, fatigue, sensory and pain disorders. Regular follow-up of patients is therefore essential to assess the evolution of their symptoms, adjust treatment, adapt therapeutic interventions and improve their quality of life. However, most consultations with the neurologist are bi-annual, and because of the long time lapse between two consultations, the practitioner often has only incomplete information on the evolution of symptoms.
To help fill these gaps, advances in digital health technologies, with the development of telemonitoring solutions, enable patients to be monitored remotely and provide a potentially more robust amount of information relating to the severity of the disease and its evolution over time. In this sense, remote monitoring in PD would enable the neurologist to readjust treatment at the right time and in the most appropriate way. This will be done by means of a weekly questionnaire (adapted from the clinical examination via the MDS-UPDRS scale) completed by the patient via a mobile application.
Remote monitoring of patients should improve their symptom management and quality of life, hence the interest in an intervention offering a remote monitoring service: DIGIPARK MONITOR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
conventional follow-up only, i.e. a consultation with the neurologist every 6 months
remote monitoring using the DIGIPARK MONITOR application in addition to conventional monitoring.
Device: DIGIPARK MONITOR
remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
Clinical effectiveness of telemonitoring on symptom progression in PD patients assessed by Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS)
total clinical examination score using the Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS). Score range from 0 to 200. A high score indicates clinical deterioration
Time frame: 6 months
Evolution of PD patients' symptoms assessed by Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS)
Total clinical examination score using the Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS). Score range from 0 to 200. A high score indicates clinical deterioration
Time frame: 12 months
Specific quality of Life assessed by Parkinson Disease Questionnaire (PD-Q39).
score of Parkinson Disease Questionnaire (PD-Q39). Score range from 0 to 100. A high score indicates a deterioration
Time frame: 12 months
General quality of Life assessed by EuroQol-5 dimensions questionnaire
Score of EuroQol-5 dimensions questionnaire. Score range from 0 to 100. A high score indicates a improvement
Time frame: 12 months
Organizational impact assessed by the number of consultation that led to a paramedical and/or drug treatment rehabilitation between semi-annual consultations
Percentage of patients who had a consultation that led to a paramedical and/or drug treatment rehabilitation between semi-annual consultations
Time frame: 12 months
Medico-economic impact
Average total cost at 12 months in each group
Time frame: 12 months
Usability assessed by System Usability Scale.
System Usability Scale. Score range from 1 to 100. A high score indicates a improvement
Time frame: 12 months
User's satisfaction assessed by a spécific questionnaire created for the study
Satisfaction questionnaire created specifically for the study.Score range from 1 to 100. A high score indicates a improvement
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2024; primary completion for Jan 2027, 30 months later.
Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 30 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.